Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures (FOS)
Primary Purpose
Epilepsy
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Placebo
High Dose Fish Oil
Low Dose Fish Oil
Sponsored by
About this trial
This is an interventional prevention trial for Epilepsy focused on measuring epilepsy, cardiac risk factors, memory, cognition, n-3 fatty acids, fish oil, EPA, DHA, seizures
Eligibility Criteria
Inclusion Criteria:
- Male or female, age 18 - 70
- History of intractable localization related/partial onset seizures and generalized tonic/clonic or tonic seizures defined according to International League Against Epilepsy (ILAE) classification as:
- A history compatible with localization related partial epilepsy
- A history of generalized tonic clonic or tonic seizures with loss of consciousness
- Three or more simple partial, complex partial or tonic-clonic seizures per month
- An EEG and/or an MRI consistent with a localization related epilepsy
- Evidence of at least three seizures per month for at least two months prior to the study
- Exposure to at least one antiepileptic drug at adequate dose
Exclusion Criteria:
- Significant or progressive medical, cardiac, or other illness
- Allergy to fish products or fish oil
- History of a coagulation disorder
- History of non-epileptic seizures
- Consumption of Fish Oil at any time 30 days or less prior to enrollment
- Any change in antiepileptic drugs for 30 days or less prior to enrollment
- Treatment with Warfarin for 30 days or less prior to enrollment
- Previous poor compliance with therapy
- Drug or alcohol abuse
- Uncountable seizures as a result of seizure clustering, or inadequate supervision if the patient cannot count their own seizures.
- Pregnancy
Sites / Locations
- UCLA General Clinical Research Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Placebo Comparator
Experimental
Experimental
Arm Label
Placebo
High Dose Fish Oil
Low Dose Fish Oil
Arm Description
Corn Oil Placebo (n-6 fatty acids)
2160 mg of EPA + DHA
1060 mg of EPA + DHA
Outcomes
Primary Outcome Measures
Seizure Frequency
Seizure frequency (seizures per day or seizures per month)
Secondary Outcome Measures
Full Information
NCT ID
NCT00871377
First Posted
March 27, 2009
Last Updated
January 9, 2014
Sponsor
National Center for Complementary and Integrative Health (NCCIH)
1. Study Identification
Unique Protocol Identification Number
NCT00871377
Brief Title
Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures
Acronym
FOS
Official Title
Pilot Randomized Double Blind Crossover Study Of Fish Oil [Eicosapentaenoic Acid (EPA) And Docosahexaenoic Acid (DHA)] For Intractable Partial Seizures
Study Type
Interventional
2. Study Status
Record Verification Date
January 2014
Overall Recruitment Status
Completed
Study Start Date
May 2008 (undefined)
Primary Completion Date
May 2011 (Actual)
Study Completion Date
August 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
National Center for Complementary and Integrative Health (NCCIH)
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to determine if Omega-3 fatty acids reduce seizures and modify cardiac risk factors in people with epilepsy.
Detailed Description
Epilepsy is a common and disabling condition, characterized by recurrent seizures. Sudden unexpected death (SUDEP) is a major cause of mortality in people with epilepsy. SUDEP accounts for up to 20% of all cause mortality, and is most common in younger people, especially in their 20's to 40's year olds. In those with drug resistant epilepsy, SUDEP is five times more common than in well-controlled epilepsy. Likely causes of death include cardiac arrhythmias due to impaired autonomic regulation and reduced heart rate variability. Similarly, patients with recent myocardial infarction and congestive heart failure are at higher risk for sudden death, and manifest markedly reduced heart rate variability. Clinical studies of heart disease indicate that n-3 fatty acids, prevent cardiac arrhythmias, reduce mortality after myocardial infarction, and reduce the risk of sudden cardiac death. The mechanism by which EPA and DHA exert their anti-arrhythmia effect is due to inactivation of high frequency sodium and L-type calcium channels in the heart. In addition, n-3 fatty acids improve HRV in cardiac patients, and this reduction in HRV is postulated to be a marker of the anti-arrhythmic effect of n-3 fatty acids. Preliminary data from our group indicates that n-3 fatty acids improve HRV in people with epilepsy, especially those with low HRV (SDNN < 50). The commonality between n-3 fatty acids and improvement in HRV in patients with heart disease and epilepsy serves as a basis for our hypothesis that n-3 fatty acids may reduce the risk of SUDEP in epilepsy. The purpose of this proposal is to determine if n-3 fatty acids reduce seizures and modify cardiac risk in people with epilepsy who are at risk of SUDEP.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Epilepsy
Keywords
epilepsy, cardiac risk factors, memory, cognition, n-3 fatty acids, fish oil, EPA, DHA, seizures
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
24 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Corn Oil Placebo (n-6 fatty acids)
Arm Title
High Dose Fish Oil
Arm Type
Experimental
Arm Description
2160 mg of EPA + DHA
Arm Title
Low Dose Fish Oil
Arm Type
Experimental
Arm Description
1060 mg of EPA + DHA
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Corn Oil
Intervention Description
corn oil (n-6 fatty acids)
Intervention Type
Drug
Intervention Name(s)
High Dose Fish Oil
Intervention Description
n-3 fatty acids, 1060 mg EPA + DHA
Intervention Type
Drug
Intervention Name(s)
Low Dose Fish Oil
Intervention Description
n-3 fatty acids, 2160 mg EPA + DHA
Primary Outcome Measure Information:
Title
Seizure Frequency
Description
Seizure frequency (seizures per day or seizures per month)
Time Frame
Study completion (42 weeks)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female, age 18 - 70
History of intractable localization related/partial onset seizures and generalized tonic/clonic or tonic seizures defined according to International League Against Epilepsy (ILAE) classification as:
A history compatible with localization related partial epilepsy
A history of generalized tonic clonic or tonic seizures with loss of consciousness
Three or more simple partial, complex partial or tonic-clonic seizures per month
An EEG and/or an MRI consistent with a localization related epilepsy
Evidence of at least three seizures per month for at least two months prior to the study
Exposure to at least one antiepileptic drug at adequate dose
Exclusion Criteria:
Significant or progressive medical, cardiac, or other illness
Allergy to fish products or fish oil
History of a coagulation disorder
History of non-epileptic seizures
Consumption of Fish Oil at any time 30 days or less prior to enrollment
Any change in antiepileptic drugs for 30 days or less prior to enrollment
Treatment with Warfarin for 30 days or less prior to enrollment
Previous poor compliance with therapy
Drug or alcohol abuse
Uncountable seizures as a result of seizure clustering, or inadequate supervision if the patient cannot count their own seizures.
Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christopher M DeGiorgio, MD
Organizational Affiliation
David Geffen - UCLA School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
UCLA General Clinical Research Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
18721899
Citation
DeGiorgio CM, Miller P, Meymandi S, Gornbein JA. n-3 fatty acids (fish oil) for epilepsy, cardiac risk factors, and risk of SUDEP: clues from a pilot, double-blind, exploratory study. Epilepsy Behav. 2008 Nov;13(4):681-4. doi: 10.1016/j.yebeh.2008.08.001. Epub 2008 Sep 7.
Results Reference
background
PubMed Identifier
18634902
Citation
DeGiorgio CM, Miller P. n-3 fatty acids (eicosapentanoic and docosahexanoic acids) in epilepsy and for the prevention of sudden unexpected death in epilepsy. Epilepsy Behav. 2008 Nov;13(4):712-3. doi: 10.1016/j.yebeh.2008.06.017. Epub 2008 Aug 9. No abstract available.
Results Reference
background
PubMed Identifier
20667792
Citation
DeGiorgio CM, Miller P, Meymandi S, Chin A, Epps J, Gordon S, Gornbein J, Harper RM. RMSSD, a measure of vagus-mediated heart rate variability, is associated with risk factors for SUDEP: the SUDEP-7 Inventory. Epilepsy Behav. 2010 Sep;19(1):78-81. doi: 10.1016/j.yebeh.2010.06.011. Epub 2010 Jul 27.
Results Reference
result
PubMed Identifier
26696953
Citation
Novak JL, Miller PR, Markovic D, Meymandi SK, DeGiorgio CM. Risk Assessment for Sudden Death in Epilepsy: The SUDEP-7 Inventory. Front Neurol. 2015 Dec 9;6:252. doi: 10.3389/fneur.2015.00252. eCollection 2015.
Results Reference
derived
PubMed Identifier
25201887
Citation
DeGiorgio CM, Miller PR, Harper R, Gornbein J, Schrader L, Soss J, Meymandi S. Fish oil (n-3 fatty acids) in drug resistant epilepsy: a randomised placebo-controlled crossover study. J Neurol Neurosurg Psychiatry. 2015 Jan;86(1):65-70. doi: 10.1136/jnnp-2014-307749. Epub 2014 Sep 8.
Results Reference
derived
Links:
URL
http://www.centerwatch.com/clinical-trials/listings/studydetails.aspx?StudyID=140859
Description
CenterWatch Listing
Learn more about this trial
Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures
We'll reach out to this number within 24 hrs